A 61603 hydrobromide |
| Catalog No.GC14527 |
Un bromhydrate 61603 est un agoniste sélectif des récepteurs α1A-adrénergiques.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 107756-30-9
Sample solution is provided at 25 µL, 10mM.
A 61603 hydrobromide is a potent and selective agonist of α1A-adrenoceptor [1].
α1A-adrenoceptor (α1A-AR) belongs to α1- adrenergic receptors, which include three subtypes α1A, α1B and α1D and play an important role in regulating cell growth and proliferation.
A 61603 hydrobromide is a potent and selective α1A-adrenoceptor agonist. A-61603 was 35-fold more potent at α1A-AR than at α1B-AR or α1D-AR. In fibroblast cells transfected with α1A-AR, A-61603 significantly stimulated phosphoinositide hydrolysis [1]. A 61603 exhibited affinity for α1A-AR, α1B-AR and α1D-AR with pKi values of 8.05/7.52, 5.68 and 5.87, respectively. Also, A 61603 exhibited agonist activities for α1A-AR, α1B-AR and α1D-AR with pEC50 values of 8.24/7.66, 6.50 and 5.59, respectively [2]. In neonatal rat ventricular myocytes, A61603 significantly increased the frequency of Ca2+ transients with EC50 value of 6.9 nM in a dose-dependent way [3]. In mesenteric vascular bed isolated from mice, A61603 significantly increased perfusion pressure with 235-fold higher potency than phenylephrine, which suggested that α1A-AR plays an important role in the control of blood pressure [4].
References:
[1]. Knepper SM, Buckner SA, Brune ME, et al. A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther, 1995, 274(1): 97-103.
[2]. Meyer MD, Altenbach RJ, Hancock AA, et al. Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. J Med Chem, 1996, 39(20): 4116-4119.
[3]. Luo DL, Gao J, Fan LL, et al. Receptor subtype involved in alpha 1-adrenergic receptor-mediated Ca2+ signaling in cardiomyocytes. Acta Pharmacol Sin, 2007, 28(7): 968-974.
[4]. Martínez-Salas SG1, Campos-Peralta JM, Pares-Hipolito J, et al. Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol, 2007, 27(3): 137-142.
| Cas No. | 107756-30-9 | SDF | |
| Chemical Name | (S)-N-(5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)methanesulfonamide hydrobromide | ||
| Canonical SMILES | OC1=C(C2=C(C=C1)[C@@H](C3=NCCN3)CCC2)NS(=O)(C)=O.Br | ||
| Formula | C14H19N3O3S.HBr | M.Wt | 390.29 |
| Solubility | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5622 mL | 12.811 mL | 25.622 mL |
| 5 mM | 512.4 μL | 2.5622 mL | 5.1244 mL |
| 10 mM | 256.2 μL | 1.2811 mL | 2.5622 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















